A large amount of epidemiological and experimental studies suggests that NLRP3 inflammasome plays a pivotal role in the pathogenesis of atherosclerosis,11, 46, 47, 48 driving the discovery of a series of exogenous and endogenous inhibitors that exert anti‐inflammatory effects by inhibiting NLRP3 inflammasome activation or IL‐1 cytokine secretion.9, 49. Here, IL1B is linked to atherosclerosis.